Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00022958
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2001-08-16
Brief Title:
Expanded Access Study of Iodine-131 Anti-B1 Antibody
Sponsor:
Corixa Corporation
Organization:
Corixa Corporation
Study Overview
Official Title:
Expanded Access Study of Iodine-131 Anti-B1 Antibody for RelapsedRefractory Low-Grade and Transformed Low-Grade Non-Hodgkins Lymphoma
Status:
UNKNOWN
Status Verified Date:
2004-08
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to make Iodine-131 Anti-B1 Antibody more broadly available to patients Secondary endpoints of the study will be to obtain additional information on the efficacy and safety of Iodine-131 Anti-B1 Antibody
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None